BioLineRx (BLRX) Retained Earnings (2011 - 2026)

BioLineRx's Retained Earnings history runs 15 years deep, the most recent figure standing at -$401.0 million for Q4 2025.

• In Q4 2025, Retained Earnings changed 0.29% year-over-year to -$401.0 million; the TTM figure through Dec 2025 stood at -$401.0 million (changed 0.29% YoY), while the FY2025 annual figure was -$401.0 million, changed 0.29% from the prior year.
• Retained Earnings for Q4 2025 stood at -$401.0 million, roughly flat from -$399.6 million in the prior quarter.
• The five-year high for Retained Earnings was -$288.2 million in Q1 2021, with the low at -$401.0 million in Q4 2025.
• The 5-year median for Retained Earnings is -$368.7 million (2023), against an average of -$355.7 million.
• The sharpest annual moves came in 2023 and 2025: Retained Earnings declined 18.37% in 2023, then declined 0.29% in 2025.
• BioLineRx's Retained Earnings stood at -$305.0 million in 2021, then decreased by 8.18% to -$330.0 million in 2022, then declined by 18.37% to -$390.6 million in 2023, then fell by 2.36% to -$399.8 million in 2024, then slipped by 0.29% to -$401.0 million in 2025.
• Business Quant data shows BLRX's Retained Earnings at -$401.0 million in Q4 2025, -$399.6 million in Q3 2025, and -$398.6 million in Q2 2025.